Codexis

Codexis Debt/EBITDA

The Total Debt to EBITDA Ratio of Codexis (CDXS) as of Sep 26, 2026 is -1.75. In the previous year, Total Debt to EBITDA Ratio was -1.12 — a change of 57.18% (lower).

Debt/EBITDA

-1.75

YoY

57.18%

Last updated:

Total Debt to EBITDA Ratio of Codexis is 2026 -1.75 . Total Debt to EBITDA Ratio of Codexis was 2025 -1.12 . It decreases by 57.18% lower compared to the previous year.

The Codexis Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2018
-0.04 USD
Jan 1, 2019
-2.08 USD
Jan 1, 2020
-1.04 USD
Jan 1, 2021
-2.10 USD
Jan 1, 2022
-1.25 USD
Jan 1, 2023
-0.24 USD
Jan 1, 2024
-1.12 USD
Jan 1, 2025
-1.75 USD
The Codexis Debt/EBITDA history
YEARDebt/EBITDAYoY
-1.75+57.18%
-1.12+374.03%
-0.24-81.18%
-1.25-40.41%
-2.10+101.28%
-1.04-49.88%
-2.08+4,737.05%
-0.04+35.95%
-0.03-36.22%
-0.05-9.27%
-0.05—
0.00—
Access this data via the Eulerpool API

Codexis Stock analysis

What does Codexis do? Codexis Inc. is an American biotechnology company that specializes in developing innovative biological solutions for a variety of industries. The company was founded in 2002 and is headquartered in Redwood City, California. Business Model: Codexis is service-oriented and provides customized enzyme solutions for companies looking to improve their products through sustainable processes. The company has developed a unique platform called Rational Protein Engineering, which allows for the development of specific enzymes for various industries. Customers benefit from enzyme optimization expertise and know-how. Divisions: Codexis operates in the fields of life sciences, materials science, agrochemicals, and biofuels. 1. Life Sciences: Codexis specializes in the production of enzymes and biocatalysts for the pharmaceutical industry in the life sciences division. The goal is to provide a faster and more efficient manufacturing process for pharmaceutical active ingredients. The company has successfully developed active ingredients for antibodies, lipids, uric acid, and antivirals. 2. Materials Science: In the materials science division, Codexis specializes in the production of enzymes for materials such as dyes, polymers, and cosmetic products. Codexis ensures that these products are efficiently manufactured without the use of environmentally harmful chemicals. 3. Agrochemicals: Codexis offers customized enzyme solutions to agrochemical manufacturers that reduce the use of chemicals and benefit the environment. These enzymes help in the production of pesticides and other agrochemicals. 4. Biofuels: In the biofuels division, Codexis specializes in the production of enzymes for processing corn, harvested plants, or waste products. These enzymes help enable cost-effective biofuel production. Products: Codexis has developed a wide range of products tailored to the needs of various industries. Some of the products recently introduced to the market by Codexis include: 1. CodeEvolver: CodeEvolver is a platform that allows biotechnology companies to quickly create customized enzyme solutions for their specific needs. The process is fully automated and results in a significant reduction in development time and costs. 2. Codex® screening panels: Codexis offers various screening panels that allow customers to quickly and efficiently select the enzymes best suited for their purposes. The panels are suitable for industries including pharmaceuticals, chemicals, and plant protection. 3. Codex® enzymes: Codexis offers a wide range of enzymes specifically designed for different industry needs. This includes enzymes for the production of biofuels, pesticides, cosmetic products, and pharmaceuticals. Overall, Codexis Inc. has demonstrated its ability to deepen the understanding of biocatalysts and introduce innovative biological processes in a variety of industries through its unique Rational Protein Engineering platform. Codexis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Codexis stock

Total Debt to EBITDA Ratio of Codexis is -1.75 in 2026.

Total Debt to EBITDA Ratio of Codexis changed from -1.12 to -1.75, representing a 57.18% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Codexis since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Codexis with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Codexis

All Key Metrics — Codexis